Session

From Maastricht VI to CPI therapy: Gastric cancer in 2022

Who is at risk of gastric cancer and how do I manage this risk in my practice?
Who is at risk of gastric cancer and how do I manage this risk in my practice?

From Maastricht VI to CPI therapy: Gastric cancer in 2022

Molecular biomarkers and personalised treatment of gastric cancer: Are we there yet?
Molecular biomarkers and personalised treatment of gastric cancer: Are we there yet?

From Maastricht VI to CPI therapy: Gastric cancer in 2022

Patient with advanced (EBV+) gastric cancer
Patient with advanced (EBV+) gastric cancer

From Maastricht VI to CPI therapy: Gastric cancer in 2022

How do I recognise the pre-malignant stomach and manage the early cancer?
How do I recognise the pre-malignant stomach and manage the early cancer?

From Maastricht VI to CPI therapy: Gastric cancer in 2022

Early gastric cancer
Early gastric cancer

From Maastricht VI to CPI therapy: Gastric cancer in 2022

Item 1 - 5 / 5
1